EyePoint Pharmaceuticals (vorher: PSIVIDA) startet durch !! (Seite 232)

[binda]

SK 1,93 USD = 1,537€

[binda]

pSivida Corporation expands patent portfolio, moves towards trials of drug delivery device inserter
Thursday, June 07, 2012 by Angela Kean pSivida Corporation (ASX: PVA) has taken an important step towards planned phase III trials of its posterior uveitis insert with the granting of a U.S. patent covering a new inserter developed to facilitate administration of micro-drug delivery devices.

The company has a very strong intellectual property portfolio with more than 100 granted patents in the U.S., Europe, Japan, China and Australia.

The new inserter has been designed to allow the insertion of drug delivery devices, such as pSivida’s Medidur™ implant, through a far smaller needle than was previously possible and to require much less force to administer.

Another advantage is the inserter allows for use of larger reservoir delivery devices, meaning pSivida’s Durasert™ technology can now be used with a larger number of drugs

Durasert™ is a fully bioerodible implantable delivery device system that is small enough to fit inside the barrel of a 25 gauge needle.

pSivida is using the technology to develop a long term sustained release implant of latanoprost, the most commonly prescribed agent for ocular hypertension and glaucoma.

The product candidate is designed to be administered by an eye care professional into the subconjunctival space of the eye in a minimally invasive procedure.


Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

[nanotechnolog]

.....dieser Betrag ist bei mir auch im Hinterkopf geblieben, aber Bev hat gemeint, Alimera habe das Pricing noch nicht gemacht!

[wonner]

ich bin mir nicht ganz sicher!
aber es stand mal ca. 8000-10000 dollar pdo behandlung in 36 monaten im raum!
andere kosten 2000 dollar pro injektion mit viel geringerer laufzeit
ca.1 monat!!

[binda]

06.06.2012 | 14:05
(19 Leser) Schrift ändern: 12345


(0 Bewertungen)
Business Wire · Mehr Nachrichten von Business Wire
pSivida Corp. Announces Issuance of US Patent for Inserter to Be Used in Planned Phase III Uveitis TrialspSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced it has been issued US patent No. 8,192,408 titled "Ocular Trocar Assembly" for a new inserter developed to facilitate administration of micro-drug delivery devices.

"We are very pleased with the issuance of this US patent for our new inserter," said Dr. Paul Ashton, president and CEO of pSivida. "We have designed it to allow the insertion of drug delivery devices, such as our Medidur™ implant, through a far smaller needle than was previously possible and to require significantly less force to administer. We anticipate using this new inserter in the planned Phase III trials of our posterior uveitis insert.

"Another advantage," Dr. Ashton continued, "is that the new inserter allows for use of larger reservoir delivery devices. Thus our Durasert technology can now be used with a larger number of drugs."

pSivida has a very strong intellectual property portfolio with more than 100 granted patents in the US, Europe, Japan, China and Australia.

[nanotechnolog]

Wie teuer soll denn iluvien sein pro behandlung???

[wonner]

gerade weil das geld knapp ist,so ist iluvien eine alternative zu anderen medikamenten die wesentlich teurer sind!
abwarten und tee trinken und nicht die anderen möglichkeiten aus den augen verlieren!
iluvien hat einen zulassung,also muss es funktionieren!
gut für andere anwendungen!
gleichzeitig haben wir ruhe an der optionsfront!
4,5 mio werde bis juli verfallen sein und die nächsten werden erst 2018 fällig!
also würde eine ka nicht so sehr ins gewicht fallen!
gehe davon aus,das es dieses jahr noch dazu kommen wird,sobald der kurs 3-4 dollar hat!
wenn die nachrichtenlage positiv bleibt!

es war schon mal schlechter um psivida bestellt!

[Andrija]

Antwort auf Beitrag Nr.: 43.251.266 von nanotechnolog am 05.06.12 16:04:22

...ne, weil doch die Portugiesen eh kein Geld mehr haben .

[binda]

Zitat von nanotechnolog: ...und der Kurs reagiert wie üblich nicht an der Nasdaq!! ...so pessimistisch der Finanzmarkt zur Zeit an der Börse ist!

geht so langsam los

[nanotechnolog]

...und der Kurs reagiert wie üblich nicht an der Nasdaq!! ...so pessimistisch der Finanzmarkt zur Zeit an der Börse ist!